Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
The Nasdaq Letter further provided that, pursuant to Nasdaq Listing Rule
5605(c)(4), the Company is entitled to a cure period to regain compliance with
Nasdaq Listing Rule 5605, which cure period will expire on the earlier of the
date of the Company's next annual shareholders' meeting or
The Company must submit documentation, including the biography of any new director, evidencing compliance with the Nasdaq Listing Rule 5605 no later than the compliance date described above. The Company is working diligently to comply with Nasdaq's audit committee requirements as set forth in the Nasdaq Listing Rule 5605 within the cure period provided by Nasdaq, and expects to evidence compliance to Nasdaq no later than the compliance date.
--------------------------------------------------------------------------------
© Edgar Online, source